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Abstract Takayasu arteritis is a chronic granulomatous
disease of the aorta and its major branches that usually
affects women during the second and third decades of life,
but it has been reported in young children. This review
details the clinical, pathological and radiological features,
differential diagnoses and management of the condition,
focusing chiefly on the disease in children. The recent
definition of Takayasu arteritis is discussed. The condition
should be considered in patients with unexplained arterial
hypertension or unexplained inflammatory syndromes
without signs of localization. Since the disease may be
life-threatening and progressive, early recognition is neces-
sary to initiate appropriate therapy. Patients with persistent
ischaemic symptoms including hypertension might benefit
from revascularization procedures.
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Introduction
The term ‘large vessel vasculitis’ encompasses the spectrum
of primary vasculitis that causes chronic granulomatous
inflammation predominantly of the aorta and its major
branches. The two major categories of large vessel
vasculitis are temporal (giant cell) arteritis and Takayasu
arteritis (TA). These arteritides differ in the age of onset,
with the former rarely occurring before the age of 50 years
and the latter rarely after 50 years. The classification system
for childhood vasculitides recently published under the
auspices of the European League against Rheumatism
(EULAR) and the Pediatric Rheumatology European
Society (PRES) includes TA as the only form of large
vessel vasculitis in childhood [1].
TA is an inflammatory and stenotic disease of medium-
and large-sized arteries and is characterized by a predilec-
tion for the aortic arch and its branches, hence also referred
to as the aortic arch syndrome. While the precise
pathogenesis is unknown, intimal fibroproliferation of the
aorta, great vessels, pulmonary arteries and renal arteries
results in segmental stenosis, occlusion, dilatation and
aneurysm formation in these vessels. An alternate term,
idiopathic or non-specific aortoarteritis has been used to
describe the spectrum of vascular abnormalities associated
with the condition.
History
While an Italian pathologist, Giovanni Battista Morgagni, is
credited with the first report of a patient in 1761 [2], the
first detailed description was by Savory (1856), who
described a 22-year-old woman with seizures, unilateral
blindness, scalp ulcerations and pulseless vessels in the
head, neck, and upper extremities. At postmortem exami-
nation, inflammatory thickening of the aorta and major
arteries was identified [3]. At the Annual Meeting of the
Japanese Ophthalmology Society in 1908, a Japanese
ophthalmologist, Mikito Takayasu, described ocular arterial
changes and the association of retinal arteriovenous anasto-
moses and absent upper extremity pulses [4]. Shimizu and
Sano proposed the term ‘pulseless disease’ in 1951 to
describe the triad of: (a) absent radial pulsation, (b) signs
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(c) hypotensive ophthalmoangiopathy [5]. Over the past two
decades, various expert groups, including the American
College of Rheumatology and the Chapel Hill International
Consensus Conference, have endorsed the use of the term
‘Takayasu arteritis’ to describe the condition [6, 7].
Epidemiology
TA is worldwide in distribution, with an incidence of 1.2–
2.6/million per year in the western population and perhaps a
100-times higher incidence in East Asian countries [8, 9].
The scant number of studies reporting the frequency of TA
makes it difficult for one to compare incidence rates.
TA most often affects young women in their second and
third decades of life, and the age of onset is usually
between 15 and 30 years [10]. The age of onset may vary
from infancy [11, 12] to middle age. In a series of 60
patients with TA at the National Institute of Allergy and
Infectious Diseases in North America, 30% were younger
than 20 years at diagnosis [10].
Women with TA outnumber men by 8–9:1. Female
patients (97%) were most frequently affected in a series of
patients from North American [10]. A similar gender
predilection has been observed in various reports for
children, including those from India and South Africa,
which report a female-to-male ratio of 2:1 [13, 14].
Pathology
Histological specimens are seldom available, with the
exception of specimens obtained during autopsy and bypass
surgery. The vascular pathology in TA is characterized by
segmental and patchy granulomatous inflammation of all
three layers of the aorta and major branches (Fig. 1). This
inflammation leads to arterial stenosis, thrombosis and
aneurysms. Mononuclear infiltration of the adventitia with
perivascular cuffing of the vasa vasorum occurs early.
Granulomatous changes may be observed in the tunica
media with Langerhans cells and central necrosis of elastic
fibres and smooth muscle cells. Later, fibrosis of the media
and acellular thickening of the intima may compromise the
vessel lumen. The corresponding organ shows ischaemic
changes, which largely determine the clinical features of the
disease.
Renal involvement
The commonest glomerular lesions in TA are non-specific
ischaemic changes such as collapsed and/or hyalinized
tuft resulting from arterial narrowing or long-standing
renovascular hypertension. Isolated case reports show
varied histological features, including immunoglobulin A
(IgA) nephropathy, membranoproliferative glomerulone-
phritis (GN), crescentic GN and mesangioproliferative
GN [15–17]. TA complicated by secondary amyloidosis
has been reported, with and without evidence of intercur-
rent tuberculosis [18].
Pathophysiology
The precise factor(s) responsible for the arterial damage in
TA are unknown. The presence of hypergammaglobulinae-
mia, circulating antibodies against aorta and arteries,
circulating immune complexes and a favourable response
to steroids suggest the pathogenic role of autoimmunity. It
is believed that genetically linked immune responses to
unidentified antigen(s) may incite autoimmune damage by
cell-mediated or humoral pathways, resulting in the disease
and its relapses [19, 20].
Autoantibodies against aortic endothelial cells have been
proposed as a key factor in the pathogenesis of TA.
Immunoglobulins (Igs) G, M and properdin are found in
lesions from pathology specimens. Chauhan et al. reported
that patients with TA show circulating anti-aortic endothe-
lial cell antibodies (AAECAs) directed against 60–65 kDa
heat-shock proteins (HSPs 60/65) [21]. Sera from AAECA-
positive patients with TAwere found to induce apoptosis of
aortic endothelial cells, suggesting that these antibodies
have a role in the pathogenesis. There is, however, no direct
evidence that AAECAs trigger the development of TA, and
it is possible that these autoantibodies are produced
secondary to enhanced expression of HSPs 60/65 in aortic
vascular cells, which has been induced by other mecha-
nisms. The association of TAwith perinuclear and cytoplas-
mic antineutrophilic cytoplasmic antibodies (ANCAs) also
Fig. 1 Photomicrograph (light microscopy) showing transmural
inflammation of the vessel wall
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the disease [22]. Case reports describing the association of
TA with rheumatoid arthritis, ulcerative colitis, systemic
lupus, Crohn disease, sarcoidosis and amyloidosis also
emphasize the importance of immune mechanisms in the
pathogenesis [23, 24].
Although many studies have proposed that bacteria and
viruses might have a causative role in primary vasculitides,
no specific infectious agents have been identified [20]. This
is also supported by the fact that corticosteroids are highly
effective, even in the acute inflammatory phase, while, in
infection-induced inflammatory diseases such as viral
myocarditis, corticosteroid therapy is associated with the
risk of aggravation of the inflammation.
While previous reports have suggested the association of
TA with tuberculosis, further studies have not supported
this association [25]. Although TA is common in the parts
of the world with high incidences of tuberculosis, excep-
tions such as Japan are intriguing. A proposed hypothesis
for the pathogenesis of granulomatous vasculitis suggests
that antigens deposited in vascular walls activate CD4+
T cells, release of cytokines, and monocyte chemotaxis.
These monocytes are transformed into macrophages that
mediate endothelial damage and result in granuloma
formation in the vessel walls. Seko showed that injection
of syngeneic T cells sensitized to vascular smooth muscle
cells in mice incites granulomatous vasculitis of the
pulmonary arterioles [26].
An increased incidence of skin hypersensitivity to the
purified protein derivative (PPD) has been reported in
patients with TA [27]. HSP-65 is an important antigen of
Mycobacterium tuberculosis, Bacillus Calmette-Guérin
(BCG) vaccine and many other bacterial species and is
synthesized by tissues in response to stress. There is
increasing evidence that HSP-65 may be an important
antigen inciting immune damage in TA [28, 29]. Cross-
reactivity between HSP-65 and human leukocyte antigens
(HLAs) class II molecules has been described, and
expression of HSP-65 and HLA classes I and II antigens
is markedly increased in affected aortic tissue [30]. It is
speculated that type IV hypersensitivity to PPD is a
response to the HSP and is not attributable to past or
current infection with M. tuberculosis. The precise associ-
ation of TA with tuberculosis is unclear, and the condition
of patients with TA does not improve following antituber-
culosis therapy.
Genetic susceptibility
Genetic susceptibility to the disease has been studied
extensively. The condition has been reported in identical
twins, leading to a hypothesis for a hereditary basis [31]. In
Japan and Korea, TA is associated with HLA A10, B5,
Bw52, DR2 and DR4 [32, 33]. Kasuya et al. showed that
association of TA with HLA Bw52 results in higher
incidence of coronary artery and myocardial involvement
and a worse prognosis [33]. TA is associated with HLA
B22 in the United States of America [34] and with HLA B5
and B21 in Indian patients [35].
Clinical features
The clinical features of TA are divided into an early
prepulseless systemic phase and a late occlusive phase.
Approximately half of all patients show the difficult-to-
diagnose early phase, characterized by nonspecific features
such as low-grade fever, malaise, night sweats, weight loss,
arthralgia and fatigue [5]. There is often anaemia and
marked elevation of the erythrocyte sedimentation rate
(ESR). This active phase may remit spontaneously in about
3 months or it may progress insidiously into the chronic
phase, characterized by inflammatory and obliterative
changes in the aorta and its branches [10]. In this late
occlusive phase of the disease, characteristic features of TA
appear, which include diminished or absent pulses, vascular
bruits, hypertension (as a consequence of renal artery
stenosis), mesenteric angina, retinopathy, aortic regurgita-
tion (when the ascending aorta is involved) and neurolog-
ical symptoms secondary to hypertension or ischaemia
(postural dizziness, seizures, amaurosis). Weakness of the
arterial walls may give rise to localized aneurysms. A
history of Raynaud phenomenon may be present [20]. The
frequency of arteriographic abnormalities in TA and
consequent clinical manifestations are illustrated in Table 1.
This sequential presentation is, however, likely to occur
only in a minority of patients, because the disease is usually
recurrent, leading to coexistence of various phases. Further,
there can be activity during the chronic illness, not all
patients manifest an acute phase, and some may present in
chronic phase only. A variable interval (months to years)
may separate acute from occlusive phases, during which
vascular insufficiency develops. Glomerular damage in TA
is manifested by microscopic haematuria and non-
nephrotic-range proteinuria. The presentation of nephrotic
syndrome is uncommon, except in those with complicating
amyloidosis.
Ethnic differences
A review of clinical features in TA shows geographical
variations based on the site of vascular involvement. Hata
et al. evaluated the angiographic findings of 80 Japanese
patients and 102 Indian patients with TA. Patients from
Japan showed a high frequency of involvement of the
ascending aorta, aortic arch and its branches, while
involvement of the abdominal aorta and renal arteries was
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series from India, in children and young adults, the
abdominal aorta was the commonest vessel affected [13].
In North American children with TA, lesions of the thoracic
and abdominal aorta, rather than that of the aortic arch, are
common [9]. It is not known whether these variations
reflect differing causes of TA. However, all patterns of
vascular involvement are observed in every region.
Takayasu arteritis in children
Systemic symptoms are seen in a high proportion (60–70%)
of children with TA. The usual presenting symptoms are
due to hypertension, heart failure or a neurological event.
Claudication, bruit or a missing pulse in an asymptomatic
child are uncommon presentations. TA is considered to be
the commonest cause of renovascular hypertension in Asian
children [37].
The largest paediatric series reported by Hong et al. [38]
describes 70 patients, the youngest being 3 years old.
Hypertension was the usual presentation seen in 93% of
cases. In a report on 31 patients from South Africa, arterial
hypertension was the chief feature, followed by cardiac
failure, bruits and absent pulses [14]. A report on 24
patients from India described arterial hypertension in 83%,
congestive heart failure in 16% and left ventricular
hypertrophy in 54% [13]. In a Turkish multicentre review,
TA represented 1.5% of the vasculitides in children. The
majority (71.4%) had constitutional symptoms, and hyper-
tension was found in 86% [39]. Hypertension is not only
the most common clinical presentation, but is often the sole
manifestation of TA in children [40, 41].
A review of clinical and radiological features based on
the published reports in children with TA is shown in
Table 2.
Diagnostic criteria
The diagnosis of TA is often delayed because of non-
specific clinical symptoms. The Ishikawa criteria [42],
widely used for diagnosis, are based on observations in
Japanese patients and consist of obligatory, major and
minor criteria. The obligatory criterion is age less than
40 years at diagnosis or at onset of characteristic signs and
symptoms of 1 month’s duration. The major criteria are
involvement of the right or left mid-subclavian artery, and
the minor criteria include raised ESR, carotid artery
tenderness, hypertension, aortic regurgitation, pulmonary
artery lesions and involvement of the common carotid,
brachiocephalic, descending thoracic aorta or abdominal
aorta. In addition to the obligatory criterion, the presence of
two major criteria, or one major and two or more minor
criteria, or four minor criteria, suggests a high probability
of the presence of TA [42]. These criteria have greater
sensitivity for patients with active disease than for those
with inactive disease. Geographic variations in the pattern
of arterial involvement may reduce the sensitivity of these
criteria.
Modifications have been proposed in Ishikawa’s
criteria for the diagnosis [43]. The proposed modifica-
tions include removal of the obligatory criterion of age
less than 40 years, inclusion of characteristic signs and
symptoms as a major criterion, deletion of the absence of
an aorto-iliac lesion in defining abdominal aortic lesion,
a n da d d i t i o no fc o r o n a r ya r t e r yl e s i o n .T h em o d i f i e d
proposal consists of three major criteria (including left
and right mid-subclavian artery lesions, and characteristic
signs and symptoms of at least 1 month’s duration) and
ten minor criteria (high erythrocyte sedimentation rate,
carotid artery tenderness, hypertension, aortic regurgita-
tion or annulo-aortic ectasia, pulmonary artery lesion, left
mid-common carotid lesion, distal brachiocephalic trunk
lesion, descending thoracic aorta lesion, abdominal aorta
lesion and coronary artery lesion). The presence of two
major criteria, or one major and two minor criteria, or
four minor criteria, suggests a high probability of TA
[43].
When applied to 106 Indian and 79 Japanese patients
with angiographically proven TA, the above criteria had a
sensitivity and specificity that were greater than those of the
Ishikawa and American College of Rheumatology (ACR)
Artery Abnormalities (%) Potential manifestations
Subclavian 93 Arm claudication, Raynaud phenomenon
Common carotid 58 Visual changes, syncope
Abdominal aorta 47 Abdominal pain
Renal 38 Hypertension, renal failure
Aortic arch 35 Aortic insufficiency
Vertebral 35 Visual changes
Coeliac axis 18 Abdominal pain
Pulmonary 20 Chest pain, dyspnoea
Table 1 Frequency of arterio-
graphic abnormalities and po-
tential clinical features
of arterial involvement (Kerr
et al. [10])
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prevent the possibility of under-diagnosis of TA. The ACR
criteria were developed from the comparison of 63 patients
with TA with 744 controls with other forms of vasculitis,
and six criteria were selected for classifying patients as
having TA [6] (Table 3).
In 2005 a consensus conference on childhood vasculitis,
under the auspices of the EULAR and the PRES, proposed
diagnostic criteria for various vasculitides that differ in
some respects from the ACR classification criteria. This
classification suggested the inclusion of hypertension as a
criterion for childhood TA, since this was often the only
presenting sign of the disease (Table 4)[ 1]. A prospective
validation of the proposed classification criteria was
recently reported on 87 children with TA enrolled from 97
centres in 36 countries. The sensitivity and specificity of
the new criteria were 100% and 99%, respectively, with a
kappa agreement of 0.99 between the consensus panel and
the proposed definition. The sensitivity of the ACR criteria,
in this cohort, was lower, at 79%; specificity was 100%,
and the kappa score was 0.84. The EULAR/PRES
definition, therefore, has a high sensitivity and specificity
for the classification of TA [44].
Laboratory evaluation
No specific serum markers for TA have been identified.
Complete blood count shows normochromic normocytic
anaemia (in 50% of patients), leukocytosis and throm-
bocytosis. Concentrations of acute phase reactants,
including C-reactive protein and the ESR, correlate
Table 2 Summary of clinical and radiological findings in studies on Takayasu arteritis in children. The values represent actual numbers. Dashes
indicate that data were not available
Authors Number Male Constitutional
symptoms
Hypertension Radiological involvement Number of
deaths
Renal
artery
Abdominal
aorta
Thoracic
aorta
Hong et al. [38]7 0 1 3 − 65 −− − −
Hahn et al. [14] 31 13 2 27 26 22 11 7
Jain et al. [13]2 44 − 20 18 17 5 −
Ozen et al. [39] 14 7 10 12 12 14 7 1
Al abrawi et al. [41]4 2 2 2 2 1 1 −
Shrivastava et al.
[40]
47 20 20 34 35 47 − 4
Dabague and Reyes
[70]
55 12 35 49 −− − −
Table 3 American College of Rheumatology criteria for the classification of Takayasu arteritis [6]
Criterion Definition
Age of patient at disease onset
in years
Development of symptoms or findings related to Takayasu arteritis at age <40 years
Claudication of extremities Development and worsening of fatigue and discomfort in muscles of one or more extremity while in use,
especially the upper extremities
Decreased brachial artery
pulse
Decreased pulsation of one or both brachial arteries
Blood pressure difference
>10 mmHg
Difference of >10 mmHg in systolic blood pressure between arms
Bruit over subclavian arteries
or aorta
Bruit audible on auscultation over one or both subclavian arteries or abdominal aorta
Arteriogram abnormality Arteriographic narrowing or occlusion of the entire aorta, its primary branches, or large arteries in the proximal
upper or lower extremities, not due to arteriosclerosis, fibromuscular dysplasia, or similar causes; changes are
usually focal or segmental
Takayasu arteritis is classified if at least three of the six criteria are present. The presence of three or more criteria yields a sensitivity of 90.5% and
a specificity of 97.8%
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elevated transaminase levels, hypoalbuminaemia and
hypergammaglobulinaemia [10]. The concentration of
von Willebrand factor-related antigen may be elevated.
Anti-endothelial cell antibodies are often present, and anti-
nuclear antibody is usually negative. Rheumatoid factor is
elevated in 15% of patients [20].
Imaging studies
Conventional or digital subtraction angiography is consid-
ered to be necessary for the diagnosis of TA and its
complications. Angiography shows luminal irregularity,
vessel stenosis, occlusion, dilatation or aneurysms in the
aorta or its primary branches (Figs. 2). The Takayasu
Conference (1994) proposed a classification based on
angiographic abnormalities [13]:
Type I. Classic pulseless type that affects blood vessels of
aortic arch; involving the brachiocephalic trunk,
carotid and subclavian arteries.
Type II. Affects middle aorta (thoracic and abdominal
aorta).
Type III. Affects aortic arch and abdominal aorta.
Type IV. Affects pulmonary artery in addition to any of
the above types.
A fifth type includes patients with involvement of the
coronary arteries [13].
Drawbacks to arteriography include the morbidity from
use of contrast media in patients with renal disease and the
risk of radiation exposure. Recently, computed tomography
(CT) and magnetic resonance imaging (MRI) (CT and MR
angiography) have been shown to delineate aortic mural
changes that are difficult to detect on conventional
angiography (Fig. 3). CT scanning and MR angiography
may reveal mural thickening of the aorta and luminal
narrowing and may detect inflammatory lesions prior to the
development of stenoses. Such lesions may be missed on
standard angiography.
MRI features of acute phase
Significant findings in the acute phase of TA are thickening
of the wall of the aorta and pulmonary arteries. Non-
contrast T2-weighted short inversion images may be used
to monitor oedema of the aortic wall, which suggests
inflammation in a high proportion of patients with active
disease [45]. The thickened aortic wall is enhanced on
gadolinium-enhanced images. A recent report suggests that
delayed contrast-enhanced MRI may also be a useful
technique to identify inflammation in the arterial wall
[46]. Some patients may show occlusion or pseudoaneur-
ysm formation of the aortic branches or pulmonary artery in
the acute phase.
MRI features of late phase
Significant findings include diffuse narrowing of the
descending thoracic and abdominal aorta and dilatation
of the ascending aorta. Cine-MRI may depict aortic
regurgitation caused by dilatation of the ascending aorta.
Stenotic lesions, typically affecting the proximal por-
tions, of all arteries arising from the aorta and
pulmonary artery are seen in the late phase. Occlusion
is the second most common finding. Abrupt occlusion,
abrupt transition to collateral vessels and flame-shaped
termination are characteristic. In the abdominal aorta the
renal artery is the most frequently involved branch.
Pulmonary artery involvement may also be seen in 50–
80% of patients.
Thus, MRI is useful in the accurate diagnosis of TA, has
a distinct advantage over CT imaging, and can provide
almost all anatomic information needed to enable early
treatment. If available, MRI may be the preferred technique
Table 4 EULAR classification criteria for Takayasu arteritis [1]( CT computed tomography, MRI magnetic resonance imaging, ESR erythrocyte
sedimentation rate, CRP C-reactive protein)
Requirement Description
Mandatory criterion Angiographic abnormalities (conventional, CT or MRI) of the aorta or its major branches
Plus one of these five criteria Pulse deficit or claudication of the extremities
Blood pressure discrepancy in four limbs (>10 mmHg)
Bruit over the aorta and/or its major branches
Systolic/diastolic hypertension >95th centile for height
Elevated acute phase reactants (ESR or CRP)
Takayasu arteritis is diagnosed if at least one of the five criteria is present, together with the mandatory criterion
1042 Pediatr Nephrol (2010) 25:1037–1048for the diagnosis and monitoring of the course of treatment
in patients with TA.
Other imaging studies
A gallium-67 radionuclide scan may demonstrate in-
creased uptake in the aorta and its branches. While
high-resolution ultrasonography has been used to eval-
uate and monitor disease in the common carotid and
subclavian arteries, this study is not useful in evaluating
the aorta. Chest radiography may reveal widening of the
ascending aorta, irregular descending aorta, aortic
calcifications and rib notching. Prominent pulmonary
arteries signify pulmonary hypertension, whereas oligae-
mic lungs suggest involvement of intrapulmonary
arterial branches. In the presence of hilar lymphadenop-
athy, the possibility of coexistent sarcoidosis should also
be considered [47]. Echocardiography should be per-
formed to evaluate the aortic valve and to monitor aortic
insufficiency.
Positron emission tomography and biomarkers
for assessing disease activity
2-[Fluorine-18]-fluoro-2-deoxy-D-glucose (
18F-FDG) posi-
tron emission tomography (PET) is a sensitive imaging
method in the assessment of early stages of the disease.
Increased FDG uptake by inflammatory cells in the vessel
walls allows localization of disease activity and assessment
Fig. 2 Digital subtraction angiogram showing a bilateral renal artery
stenosis in an 8-year-old girl and (b) right renal artery after dilatation
in the same patient. c Juxta-renal aortic involvement with bilateral
renal artery stenosis in a 10-year-old girl. d Tight stenosis of the distal
descending thoracic aorta in an 8-year-old girl. e Extensive thoraco-
abdominal aortic involvement (with permission). f Bilateral subclavian
artery occlusion in a 9-year-old boy. Courtesy of Prof. S. Sharma,
Department of Cardiac-Radiology, All India Institute of Medical
Sciences, New Delhi
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[48].
Tripathy et al. studied the cytokine profiles of peripheral
blood lymphocytes in patients with TA. Increased percen-
tages of high tumour necrosis factor alpha (TNF-α)- and
low interleukin (IL)-2-producing T cells were found in
active TA compared with inactive TA and controls [49].
Patients with TA also show higher numbers of γδ T-cells
than those of healthy controls [50]. Others report that
plasma levels of IL-6, IL-12 and IL-18, and metallopro-
tease 9 correlate with disease activity [51–53].
Differential diagnosis
In patients who present solely with features that suggest the
involvement of large vessels, tissue biopsies are not
possible and the diagnosis is made on the basis of
characteristic arteriographic changes combined with con-
sistent clinical features. A number of important diseases
should be considered in the differential diagnosis. These
include acute infections (mycotic aneurysms due to septi-
caemia or endocarditis), chronic infections [syphilis, tuber-
culosis, human immunodeficiency virus (HIV), leprosy],
congenital causes (aortic coarctation, middle aortic syn-
drome), hereditary disorders (Marfan syndrome, neurofibro-
matosis, Ehler–Danlos syndrome), fibromuscular dysplasia
and post-radiation therapy. Treatment of these conditions
with immunosuppressive agents may be ineffective or may
worsen the disease, emphasizing the importance of an
accurate diagnosis.
Treatment
In the absence of knowledge of its precise aetiology, the
treatment of TA is based on clinical symptoms and the
possible immunological basis of the disease. Randomized
controlled treatment trials are either lacking or based on
small numbers of patients, making evidence-based man-
agement decisions difficult. The goal of treatment is to
relieve inflammation in the arteries and prevent potential
complications.
Medical therapy
The indications for medical therapy include:
1. Active and/or early lesions not requiring surgical
intervention.
2. Surgery and balloon angioplasty not possible because
of associated co-morbidities, e.g. uncontrolled conges-
tive heart failure and progressive renal failure.
Corticosteroids
While corticosteroids have not been rigorously studied in
controlled clinical trials, they are the chief form of medical
therapy. In a series from the National Institutes of Health
(USA), prednisolone/prednisone was given at a dose of
1 mg/kg daily for 1–3 months and later tapered to an
alternate-day schedule [10]. Administration of prednisolone
improves constitutional symptoms, halts disease progres-
sion in active disease and normalizes the ESR. The
medication should be tapered to an alternate-day regimen,
preferably after 3 months. Since relapses of the disease are
common, it is recommended that therapy with cortico-
steroids be continued for 1 year following clinical remis-
sion and then tapered to discontinuation. Most patients
require treatment for extended periods.
Indications for alternative therapy
Patients who fail to respond clinically to 3 months’
treatment with prednisolone (dose 1 mg/kg daily) (cortico-
steroid resistance) or show a flare of the disease on its
tapering should be considered for alternative therapy. Since
alternative therapy also enables steroid sparing, these
medications have an important role in the therapy of
children with TA.
Methotrexate
An open-label study showed the beneficial effect of
methotrexate in 16 patients with TA and corticosteroid
Fig. 3 Contrast-enhanced CT scan showing concentric, thickened,
aortic walls of the descending thoracic aorta (with permission)
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0.3 mg/kg per week (not to exceed 15 mg/week),
increasing every 1–2 weeks to 25 mg/week with
prednisolone at 1 mg/kg daily. Combined therapy
resulted in remission rates of 81%; of those patients for
whom remission of the disease was achieved, 50% had
sustained remissions of 4–34 (mean 18) months [54].
Cyclophosphamide
Of six patients with clinical or angiographic progression of
vasculitis on daily steroid therapy who were administered
cyclophosphamide (2 mg/kg per day) orally, no progression
of vascular lesions occurred in four. Two patients showed
progressive vascular lesions after 30 months and 48 months
of therapy [55]. A single-centre experience from Turkey
suggests that induction with cyclophosphamide and cortico-
steroids is an effective and safe treatment for children with
TA. In three of the four patients that had received
cyclophosphamide (maximum total dose 150 mg/kg) with
prednisolone for 12–18 months, the disease entered
remission [56]. Intravenous treatment with cyclophospha-
mide has also been reported to confer benefit [57]. Despite
limited therapeutic data, treatment with cyclophosphamide
should be considered for patients with life-threatening
manifestations.
Mycophenolate mofetil
Mycophenolate mofetil (MMF) has been used increasingly
as an alternative medication for patients with TA. Shinjo et
al. followed ten consecutive patients with active TA who
received oral treatment with MMF (at a dose of 2 g/day) for
a mean duration of 23.3 months together with tapering
doses of prednisolone. Clinical activity resolved in all
patients, except in one who withdrew from the study
because of headache, attributed to the medication [58].
Therapy with MMF allowed tapering of the corticosteroid
dose in nine patients and significant reduction in ESR and C-
reactive protein. Treatment with MMF is a promising
alternative to steroids and cytotoxic agents. However, until
results of controlled trials become available, this therapy
should be considered as a steroid-sparing one for patients
with refractory disease that does not improve with cortico-
steroid therapy [59].
Other agents that were examined in few patients as
alternative therapy include azathioprine and cyclosporine
[60, 61] and infliximab (TNF-α receptor blocker) [62].
Hoffman et al. report the results of an open-label, multi-
centric, study on anti-TNF-α therapy in 15 patients with TA
whose condition had failed to respond to corticosteroid or
alternative immunosuppressive therapies. Treatment with
infliximab resulted in clinical improvement for 14 patients
and sustained remission for ten, who were able to
discontinue glucocorticoid therapy [63]. While initial
results are promising, the role of TNF inhibition in treating
initial disease or relapses of TA has not been established.
Given a role of matrix metalloproteinases (MMPs) in the
pathogenesis of TA [64], their inhibition by minocycline
has been proposed as a useful adjunctive therapy. Therapy
with minocycline and oral administration of corticosteroids
in patients with active TA resulted in a significant decrease
in C-reactive protein, ESR and clinical disease activity, in
association with reduced blood levels of MMP-3 and
MMP-9.
Patients with systemic hypertension and/or congestive
heart failure require appropriate therapy. Renovascular
hypertension responds poorly to drug therapy. The efficacy
of treatment with oral anticoagulants, antiplatelet agents
and vasodilators has not been established. Sildenafil may be
useful for patients with peripheral vascular compromise,
such as digital ischaemia [65] .T h e r ei sn or o l ef o r
empirical therapy with antituberculosis medications, unless
there is clear documentation of associated tubercular
disease.
Revascularization procedures
The definitive treatment of occlusive disease is surgical.
Surgical treatment should be considered for patients with
progressive TA, particularly in the absence of a response to
conventional therapy, in order to prevent complications.
The indications for surgical treatment are:
1. Hypertension from stenotic coarctation of the aorta or
renovascular disease.
2. End organ ischaemia or peripheral limb ischaemia.
3. Cerebral ischaemia.
4. Aortic or arterial aneurysms, or aortic regurgitation.
Surgery during the active phase of the disease carries
significant risk of re-occlusion and procedural complica-
tions. Surgical treatment should be delayed until the acute
phase is over. Revascularization techniques for TA include:
(a) surgical bypass grafting, (b) patch angioplasty for short-
segment lesion, (c) endarterectomy, (d) percutaneous trans-
luminal angioplasty (PCTA) and (e) vascular stenting.
PCTA can achieve high rates of initial success, as
reported by Sharma et al. (initial success rate of 82% for
33 patients with renal artery lesions) and Tyagi et al. (initial
success rate of 89% and patency rate of 79% at mean
follow up of 43 months for 45 patients) [66, 67]. The
success rate was lower at 56% in the National Institutes of
Health (NIH) cohort of 11 patients; complications including
restenosis in 45% procedures [10]. Data from the Cleveland
clinic also showed restenosis in 78% of the procedures,
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achieve high rates of initial success in TA, the long-term
results are less satisfactory.
Endovascular stenting has been used in patients with
severe stenosis and hypertension or ischaemia during the
fibrotic phase of the disease. Multiple stents have been used
in children to relieve long-segment renal artery stenosis and
attendant renovascular hypertension. Bypass/reconstruction
procedures in TA have shown better sustained patency than
that by PCTA, but long-term results report patency rates of
33% at 2 years [69]. In the NIH cohort, in 50 bypass
procedures, 24% of the patients had restenosis and 4%
suffered bypass graft thrombosis [10].
Outcome
Before the availability of sequential vascular imaging, TA
was perceived as a relatively benign disease that eventually
‘burned out’ in most patients [70]. However, longitudinal
imaging data from the NIH and the Cleveland clinic
confirm that most patients experience new lesions over
time [10, 68]. One common finding in TA is the persistence
of vascular inflammation in patients whose condition
appears to be clinically silent. Surgical specimens from
patients in whom the disease is in clinical remission have
revealed histological evidence of vasculitis in >40% of
cases [71]. Thus, most patients have a disease that is
chronic or relapsing in nature.
TA can be associated with significant morbidity, and
the likelihood of disability correlates with the number of
disease relapses [68]. Aortic valve insufficiency and
congestive heart failure are reported in 25% of patients
[10, 68] and vascular claudication sufficient to limit
routine activities in up to 40% of patients [10, 70]. The
chief causes of death include congestive heart failure,
myocardial infarction, aneurysm rupture or renal failure
[69, 72]. Lupi-Herrera et al. report a 15% mortality rate
among patients with TA; most deaths were attributed to
heart failure [69]. A cohort of 88 patients from India
showed a 5-year and 10-year survival rate of 91% and
84%, respectively [72].
While long-term follow-up data are scant, TA in children
is a serious illness, and a mortality rate of 10–30% has been
reported on follow up. In a series of 26 Mexican children
aged 3–15 years, the 5-year survival rate was 35% [70].
The presence of severe vasculitis (defined as the presence of
severe grades of hypertension, aortic regurgitation, retinop-
athy or aneurysms) and poor functional class or cardiac
involvement predict a poorer outcome. Although glucocor-
ticoid therapy alleviates symptoms, there are no convincing
studies that show that they increase survival. While the
prognosis for TA has improved, due to interventional
vascular procedures, unremitting disease activity can lead
to unsatisfactory outcomes. Further, high rates of restenosis
following vascular interventional procedures reinforce
recommendations to try to postpone surgeries until the TA
is in remission.
Questions
(Answers appear following the reference list)
1. The usual age of onset of Takayasu arteritis is:
a. 1–15 years
b. 15–30 years
c. 30–45 years
d. >45 years
2. Glomerular lesions in Takayasu arteritis include all,
except
a. Amyloidosis
b. Mesangioproliferative glomerulonephritis
c. Crescentic glomerulonephritis
d. Membranous nephropathy
3. All of the following are true of Takayasu arteritis,
except
a. Evidence of hypersensitivity to purified protein
derivative (PPD) of mycobacteria
b. Association with specific HLA types
c. Predominant involvement of the aortic arch and its
branches in patients from the Indian subcontinent
d. Presence of congestive heart failure is associated
with unfavourable outcome
4. A 10-year-old girl has Takayasu arteritis with ostial
renal artery stenosis, grade II hypertension and left
ventricular hypertrophy. Therapy that is likely to be
most effective is:
a. Combination antihypertensive therapy
b. Prednisolone, mycophenolate mofetil
c. Percutaneous angioplasty
d. Autotransplantation
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